

Neurocutaneous Disorder Industry Report: Competitive Landscape and Future Prospects

*The Business Research Company's
Neurocutaneous Disorder Industry
Report: Competitive Landscape and
Future Prospects*

LONDON, GREATER LONDON, UNITED
KINGDOM, October 14, 2025

/EINPresswire.com/ -- "Get 20% Off All
Global Market Reports With Code

ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors

The logo for The Business Research Company, featuring the text "The Business Research Company" in a serif font, with a stylized bar chart to the right. The bar chart has four bars of varying heights, with the second bar from the left being the tallest and colored green.

The Business
Research Company

The Business Research Company

What Is The Projected Market Size & Growth Rate Of The Neurocutaneous Disorder Market?

In preceding years, the market size for neurocutaneous disorder has seen considerable growth.

“

It will grow to \$3.04 billion in
2029 at a compound annual
growth rate (CAGR) of 8.2%.”

*The Business Research
Company*

The market, which was worth \$2.05 billion in 2024, is estimated to rise to \$2.22 billion in 2025, showing a compound annual growth rate (CAGR) of 8.5%. This historical growth can be credited to factors such as the rise in genetic disorders, increased awareness about rare neurological conditions, the amplification of diagnostic imaging application, a surge of patients visiting specialty clinics, and increased clinical attention towards pediatric

neurology.

Expectations for strong expansion in the [neurocutaneous disorder market size](#) are prevalent, with forecasts predicting a surge to \$3.04 billion by 2029, representing a Compound Annual Growth Rate (CAGR) of 8.2%. This surge is ascribed to several factors, such as the intensifying demand for targeted drug treatments, an upswing in clinical trial activities pertaining to uncommon diseases, a rise in partnerships among research entities, an escalating utilization of genetic examination services, and a mounting spend on neurological care within the healthcare sector. Noteworthy trends projected for this period are advancements in genomic sequencing technology, innovations in the realm of gene therapy applications, increased flow of investment into research and development for novel treatment methodologies, progress in digital health assessment instruments, and groundbreaking innovations in diagnostics based on biomarkers.

Download a free sample of the neurocutaneous disorder market report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=28278&type=smp>

What Is The Crucial Factor Driving The Global Neurocutaneous Disorder Market?

The rise in genetic disorders is anticipated to fuel the expansion of the neurocutaneous disorder market. Genetic disorders, caused by DNA anomalies in an individual, may be inherited or spontaneously occur. Neurocutaneous disorders, including tuberous sclerosis complex and neurofibromatosis, result from specific genetic mutations impacting both the nervous system and the skin, resulting in neurological symptoms and notable skin abnormalities. Innovations in genetic testing and a rise in awareness are making earlier diagnosis possible and contributing to an elevated documented prevalence. For example, the Centers for Disease Control and Prevention (CDC), a governmental agency in the US, stated in November 2024 that roughly 1 in every 33 newborns in the US is born with a birth defect, many of which are tied to genetic reasons. Hence, the escalating prevalence of genetic disorders is catalyzing the growth of the neurocutaneous disorder market.

Who Are The Emerging Players In The Neurocutaneous Disorder Market?

Major players in the Neurocutaneous Disorder Global Market Report 2025 include:

- Merck KGaA
- AbbVie Inc.
- Sanofi S.A.
- Novartis AG
- Recursion Pharmaceuticals Inc.
- Takeda Pharmaceutical Company Limited
- Labcorp Holdings Inc.
- Quest Diagnostics Incorporated
- Eurofins Scientific SE
- Fosun Pharmaceutical Group Co. Ltd.

What Are The Major Trends That Will Shape The Neurocutaneous Disorder Market In The Future?

Key players in the neurocutaneous disorder market are making substantial efforts to secure regulatory approvals to expand their range of treatments, boost patient results, and benefit from the increasing demand for cutting-edge therapies. Regulatory approvals are formal consents from government authorities that legally endorse a company to market, sell, or test a drug or treatment after verifying its safety and efficacy. For example, AstraZeneca plc, a pharmaceutical and biotechnology corporation based in the UK, obtained approval from the Food and Drug Administration (FDA) in September 2025 for selumetinib (marketed as Koselugo) for treating pediatric patients aged one or above with neurofibromatosis type 1 (NF1) who have symptomatic, non-operable plexiform neurofibromas (PNs). This approval broadens the previous usage, which encompassed children aged two or above. Selumetinib, an MEK inhibitor, functions by inhibiting the MAPK pathway involved in NF1 tumor growth. Patients are administered selumetinib orally two times a day until the disease progresses or severe side effects arise, with

the most common adverse reactions including gastrointestinal, skin, cardiac, and ocular toxins. This approval provides a crucial therapeutic alternative for young children dealing with these often disfiguring and challenging tumors, which are frequently challenging to handle surgically.

What Segments Are Covered In The Neurocutaneous Disorder Market Report?

The neurocutaneous disorder market covered in this report is segmented as

- 1) By Type Of Neurocutaneous Disorder: Neurofibromatosis, Tuberous Sclerosis Complex, Sturge-Weber Syndrome, Angiomatosis, Hypomelanosis Of Ito
- 2) By Treatment Type: Pharmacological Treatment, Surgical Intervention, Laser Therapy, Physical Therapy, Psychosocial Support
- 3) By Age Group: Pediatric Patients (0-18 Years), Adult Patients (19-65 Years), Geriatric Patients (65 Years And Above)
- 4) By Severity Of Condition: Mild Cases, Moderate Cases, Severe Cases, Critical Cases
- 5) By End User: Hospitals, Specialist Clinics, Homecare Settings, Research Organizations, Pharmaceutical Companies

Subsegments:

- 1) By Neurofibromatosis: Peripheral Neurofibromatosis, Central Neurofibromatosis, Plexiform Neurofibromatosis
- 2) By Tuberous Sclerosis Complex: Classic Tuberous Sclerosis, Infantile-Onset Tuberous Sclerosis, Adult-Onset Tuberous Sclerosis
- 3) By Sturge-Weber Syndrome: Facial Sturge-Weber Syndrome, Cerebral Sturge-Weber Syndrome, Ophthalmic Sturge-Weber Syndrome
- 4) By Angiomatosis: Generalized Angiomatosis, Localized Angiomatosis, Mixed Angiomatosis
- 5) By Hypomelanosis Of Ito: Linear Hypomelanosis, Segmental Hypomelanosis, Whorled Hypomelanosis

View the full neurocutaneous disorder market report:

<https://www.thebusinessresearchcompany.com/report/neurocutaneous-disorder-global-market-report>

Which Region Is Projected To Hold The Largest Market Share In The Global Neurocutaneous Disorder Market?

In 2024, North America held the leading position in the global market for neurocutaneous disorders. The region expected to witness the quickest growth over the forecast period is Asia-Pacific. The Neurocutaneous Disorder Global Market Report 2025 encompasses regions such as Asia-Pacific, Western Europe, Eastern Europe, North America, South America, and Middle East and Africa.

Browse Through More Reports Similar to the Global Neurocutaneous Disorder Market 2025, By [The Business Research Company](#)

Cutaneous Lupus Erythematosus Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/cutaneous-lupus-erythematosus-global-market-report>

Peripheral Neuropathy Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report>

Scleroderma Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/scleroderma-global-market-report>

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:

• LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/857716697>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.